1. DATE ISSUED MM/DD/YYYYY 2. CFDA NO. 3. ASSISTANCE TYPE 06/28/2018 93.268 Project Grant 1a. SUPERSEDES AWARD NOTICE dated 08/01/2017 except that any additions or restrictions previously imposed remain in effect unless specifically rescinded 4. GRANT NO. 5. ACTION TYPE Post Award Amendment 6 NH23IP000725-05-02 Formerly 5H23IP000725-03 6. PROJECT PERIOD MM/DD/YYYY MM/DD/YYYY Through 01/01/2013 06/30/2019 7. BUDGET PERIOD MM/DD/YYYY MM/DD/YYYY From Through 04/01/2017 06/30/2019

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Office of Financial Resources

2920 Brandywine Road Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations) PHS 317, 42 USC, SEC. 247B

8. TITLE OF PROJECT (OR PROGRAM)

KY IMMUNIZATION PROGRAM IMMUNIZATION & VACCINE FOR CHILDREN PROGRAM

0- 004	NTEE NAME AND ADDRESS		I				
	n & Family Services, Kentucky Cabinet for			EE PROJECT DIRECTOR RT L. BRAWLEY, MD			
275 E	Main St			IN STREET			
Epide	miology & Health Planning-DUP		STATE BU	JDGET BRANCH, ADMINISTRAT			
Frank	fort, KY 40601-2321		FRANKFO	PRT, KY 40621			
			Phone: (50	02) 564-4478			
10a. GR	ANTEE AUTHORIZING OFFICIAL		10b. FEDER	AL PROJECT OFFICER			
	nnie Gayle White M.D.			wartz-Kitchens			
	Main Street		1600 Clifto				
	of Health Equity		Atlanta, GA				
	ort, KY 40621-0001 : 502-564-3970		Phone: 404	4-639-8596			
FIIOHE	302-304-3970						
11 APPI	ROVED BUDGET (Excludes Direct Assistance)	ALL AMOUNTS AR		IN USD COMPUTATION			
	cial Assistance from the Federal Awarding Agency Only			of Federal Financial Assistance (from	item 11m)		9,416,498.00
	project costs including grant funds and all other financial part	ticipation		obligated Balance From Prior Budget	,		0.00
				mulative Prior Award(s) This Budget P			5,030,210.00
a.	Salaries and Wages	2,554,067.00		T OF FINANCIAL ASSISTANCE THIS			4.386.288.00
b.	Fringe Benefits	2,333,032.00	13. Total Fe	deral Funds Awarded to Date for Pr	oject Period		27,590,457.00
C.	Total Personnel Costs	4,887,099.00		MENDED FUTURE SUPPORT the availability of funds and satisfactor	n, nyanyana af tha	- vo io o4):	, ,
d.	Equipment	0.00	(Subject to	the availability of furius and satisfactor	y progress or the p	ргојест).	
e.	Supplies		YEAR	TOTAL DIRECT COSTS	YEAR	TOTAI	DIRECT COSTS
f	Travel	189,109.00	a. 6		d. 9		
1.		261,791.00	b. 7		e. 10		
g.	Construction	0.00	c. 8		f. 11		
h.	Other	295,364.00	15. PROGRAM ALTERNATIVI	M INCOME SHALL BE USED IN ACCORD WITH (ES:	ONE OF THE FOLLOW	ING	
i.	Contractual	2,899,843.00	a. b.	DEDUCTION ADDITIONAL COSTS			b
<u>j</u> .	TOTAL DIRECT COSTS	8,533,206.00	c. d. e.	MATCHING OTHER RESEARCH (Add / Deduct Option) OTHER (See REMARKS)			
k.	INDIRECT COSTS	883,292.00		,			
			ON THE ABOV	RD IS BASED ON AN APPLICATION SUBMITTE E TITLED PROJECT AND IS SUBJECT TO THE TI ENCE IN THE FOLLOWING:			
I.	TOTAL APPROVED BUDGET	9,416,498.00	a.	The grant program legislation			
	F 1 101		b. c.	The grant program regulations. This award notice including terms and conditions	, if any, noted below uno	der REMARKS.	
m.	Federal Share	9,416,498.00	d. In the event th	Federal administrative requirements, cost princip tere are conflicting or otherwise inconsistent p			
n. Non-Federal Share 0.00				otance of the grant terms and conditions is ac the grant payment system.			
RE	MARKS (Other Terms and Conditions Attached -	Yes	No)				

GRANTS MANAGEMENT OFFICI Jon Messick, Grants Management Officer

17. OBJ C	CLASS 41.51	18a	. VENDOR CODE	16106	00439	B5	18b. E	IN	610600439	19. DUNS	927049767	2	20. CONG. DIST. 06
FY-ACCOUNT NO.			DOCUMENT NO.			CFDA			ADMINISTRATIVE CODE	AMT	ACTION FIN ASST		APPROPRIATION
21. a.	7-939ZRWL	b.	000725IP15		C.	93.26	58	d.	IP	e.	\$0.00	f.	75-17-0951
22. a.	7-939ZRYH	b.	000725IP15		C.	93.26	58	d.	IP	e.	\$0.00	f.	75-17-0951
23. a.	8-93907PV	b.	000725IP15		C.	93.26	58	d.	IP	e.	\$20,928.00	f.	75-18-0951

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of	2	DATE ISSUED
		06/28/2018
GRANT NO.	6 NH	I23IP000725-05-02

FY-ACCOUNT NO.	DOCUMENT NO.	CFDA	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
24.a. 8-93909KZ	b. 000725IP15	c. 93.268	d. IP	e. \$2,659,334.00	f. 75-X-0951
25.a. 8-93909LM	b. 000725IP15	c. 93.268	d. IP	e. \$390,162.00	f. 75-75-X-0512-009
26.a. 8-93909LP	b. 000725IP15	c. 93.268	d. IP	e. \$36,998.00	f. 75-75-X-0512-009
27.a. 8-93909LS	b. 000725IP15	c. 93.268	d. IP	e. \$550,783.00	f. 75-75-X-0512-009
28.a. 8-939ZRWL	b. 000725IP15	c. 93.268	d. IP	e. \$266,087.00	f. 75-18-0951
29.a. 8-939ZRYH	b. 000725IP15	c. 93.268	d. IP	e. \$461,996.00	f. 75-18-0951
30.a. 7-93900PH	b. 000725IP15	c. 93.268	d. IP	e. \$0.00	f. 75-17-0951
31.a. 7-93907HW	b. 000725IP15	c. 93.268	d. IP	e. \$0.00	f. 75-75-X-0512-009
32.a. 7-93907JY	b. 000725IP15	c. 93.268	d. IP	e. \$0.00	f. 75-75-X-0512-009
33.a. 7-93907K0	b. 000725IP15	c. 93.268	d. IP	e. \$0.00	f. 75-75-X-0512-009
34.a. 7-93907P3	b. 000725NC16PPHF17	c. 93.539	d. IP	e. \$0.00	f. 75-X-0951

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$1,333.00	\$6,135.00	\$7,468.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$1,333.00	\$6,135.00	\$7,468.00

AWARD ATTACHMENTS

Health & Family Services, Kentucky Cabinet for

6 NH23IP000725-05-02

1. TERMS AND CONDITIONS

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP13-1301, entitled Immunization and Vaccines for Children Program, and application dated March 29, 2018, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Supplemental funding in the amount of \$4,386,288 is approved for the Year 5 budget period, which is April 1, 2017 through June 30, 2019. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out efforts under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

Program Assessment

- CDC will provide guidance, trainings, tools and technical assistance to enable awardees to gain knowledge about
 program evaluation through NIC or other trainings and workshops, webinars and conference calls, and resources
 from other CDC programs and external organizations shared via
 http://www.cdc.gov/vaccines/programs/progeval/default.htm.
- CDC will provide the templates for the required Program Evaluation Topic Report, the Program Evaluation Plan, the Program Evaluation Final Report and the annual Program Evaluation Progress Report; CDC will review and provide feedback on these documents.
- CDC will review, as needed, data collection methodology and instruments developed by the awardee for their program evaluation.
- CDC evaluation staff will join project officers via conference call to review progress on program evaluation during site visits.
- CDC will assist, as needed, with interpretation of the program evaluation findings
- CDC will assist, as needed, with dissemination and publication of the program evaluation findings.
- CDC will provide resources to enable recipient to have appropriate and timely evidence-based education, training
 and communication materials. This can include technical assistance to sustain partnership development.
- CDC will analyze and report results of annual surveys regarding national, state and selected local level child, adolescent and adult immunization vaccination coverage.
- CDC will assist, as needed, in the interpretation, use, dissemination and publication of CDC-acquired and program-acquired vaccination coverage data.
- CDC will participate in the approval and design of sampling methods for school enterer vaccination coverage

surveys.

- CDC will assist, as needed, in the development of data collection and reporting methods for school-enterer vaccination coverage data.
- CDC will work with awardees and the BRFSS program at CDC to assess and develop vaccine coverage
 questions and provide state-level coverage estimates for vaccine coverage monitored through BRFSS.CDC will
 support quarterly meetings (by teleconference or, when possible, in person) of the National Adult Immunization
 Coordinators' Partnership to facilitate updates on issues specific to adult immunization.
- CDC will provide standards, guidance, and trainings on the AFIX process to assist awardees implement their quality improvement programs.
- CDC will analyze and report results of selected surveillance indicators for national surveillance data received electronically by CDC from jurisdictions, and will assist jurisdictions in the interpretation and use of those indictors.

Vaccine Access

- CDC will participate in the management of vaccine ordering through guidance, approval, and regular monitoring of the Cost and Affordability Tool and the Vaccine Ordering and Forecasting Application. Immunization information technology infrastructure
- CDC will support the production of guidance on topics impacting IIS operations.
- CDC will support the production and maintenance of IIS electronic interface guidance.
- CDC will advance activities to promote EXIS connections and business operations to Vaccine Tracking System (VTrckS).
- CDC will advance technology improvement areas to support immunization programs, including vaccine barcoding and clinical decisions support.
- CDC will develop and support improvements in IIS data quality and program evaluation measures to assess IIS
 performance. This includes comparing and reporting IIS evaluation measures against other vaccination and
 program standards.
- CDC will support the development of analytic methodologies to assess vaccination coverage using IIS data
- CDC will collaborate with external partners to promote IIS in national health IT initiatives.

Preparedness

- CDC will analyze and report results of annual surveys of awardee plans and activities related to preparedness.
- CDC will design and develop additional tools to assess awardee preparedness and coordination with preparedness offices for vaccine preventable disease outbreak and pandemic response as needed.

Direct Assistance (DA): DA is awarded in the amount of \$6,135 for 317 Operations in this budget period.

Technical Review Statement Response Requirement: The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the technical review weaknesses, recommendations, and more information needed comments from the CDC Program staff in these statements must be submitted electronically to **eGrATIS.** A copy of the response must be submitted in Grant Notes section of the Grants Management Module in GrantSolutions, no later than 60 days from the budget period start date. Failure to submit the required information by the due date, September 3, 2018, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Budget Revision Requirement: By September 3, 2018 the recipient must submit a revised budget to match the approved amount with a narrative justification. The submission must include a cover letter which bears the signature of the authorized organization representative and uploaded in the Grant Notes section of the Grants Management Module in

GrantSolutions. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

<u>Addition alternative</u>: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

Funding Restrictions

Restrictions, which must be taken into account while writing the budget, are as follows:

- · Recipients may not use funds for research.
- · Recipients may not use funds for clinical care.
- Recipients may only expend funds for reasonable program purposes, including personnel, travel, supplies, and services, such as contractual.
- Recipients may not generally use HHS/CDC/ATSDR funding for the purchase of furniture or equipment. Any such
 proposed spending must be identified in the budget.
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying
 out project objectives and not merely serve as a conduit for an award to another party or provider who is
 ineligible.
- Reimbursement of pre-award costs is not allowed.

Indirect Costs:

Indirect costs are approved based on the recipient's approved Cost Allocation Plan dated September 30, 2014.

REPORTING REQUIREMENTS

Prevention Fund Recipient Reporting Rescission: Effective May 31, 2018, CDC grant award recipients that complete projects or activities which are funded under the Prevention and Public Health Fund (PPHF) (Section 4002 of Public Law 111-148) are no longer required to report separately on their use of PPHF funds, or distinguish sub-recipients use of PPHF funds. The rescission of PPHF reporting requirements does not alter or change administrative, programmatic, financial, or other reporting requirements indicated in a Notice of Award.

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the "Account". Funds must be used in support of approved activities in the NOFO and the approved application. All award funds must be tracked and reported separately.

This award contains funding from multiple components. The grant document number identified beginning at the bottom of Page 1 of the Notice of Award and below subaccount title must be known in order to draw down funds.

Component: NON-PPHF	
Document Number: 000725IP15	
Subaccount Title: IP131301IMMVACCHIL15	

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:

Freda Johnson, Grants Management Specialist Centers for Disease Control and Prevention Infectious Disease Services Branch 2920 Brandywine Rd, MS E-15 Atlanta, GA 30341

Telephone: 770-488-3107 Fax: 770-488-2868

Email: FJohnson5@cdc.gov

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

GMO Contact:

Jon Messick, Grants Management Officer Centers for Disease Control and Prevention Infectious Disease Services Branch 2920 Brandywine Rd, MS E-15 Atlanta, GA 30341 Telephone: 770-488-1005

Fax: 770-488-2868 Email: yfa4@cdc.gov